All In Biotech

Drug Trial Radar · NCT00234897

Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis

Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)

Last checked: Nov 19, 2026Latest source record: Aug 29, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,938 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,938

Actual

Start

Aug 2004

Primary completion

Not stated

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Oct 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment

Conditions

  • Rheumatoid Arthritis

Interventions

  • adalimumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient reported outcomes, clinical response indicators.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Global Medical Information - Abbott

    North Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.